Background/Aim: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating side-effect of taxane-based treatments. This study aimed to assess the efficacy and safety of a combined compression and cooling therapy for CIPN prevention in patients with lung cancer receiving taxane-containing regimens. Patients and Methods: We retrospectively analyzed 53 patients with advanced lung cancer treated with taxane-based chemotherapy between April 2021 and March 2023. Patients underwent compression therapy using surgical gloves and elastic stockings, combined with cooling gloves and foot ice pillows, during chemotherapy infusion. Results: CIPN incidence was 20.8%, with no cases of grade ≥3 neuropathy. Paclitaxel and nab-paclitaxel showed lower CIPN rates (19.0% and 15.0%, respectively) compared to docetaxel (33.3%). No patients required chemotherapy dose reductions, and adverse events related to the therapy were mild and reversible. Conclusion: Combined compression and cooling therapy appears to be a safe, feasible, and non-pharmacologic strategy for reducing CIPN in taxane-treated lung cancer patients. Further prospective validation is warranted.
Nakajima et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: